--- title: "U.S. stock market midday update: Jasper Therapeutics up 12.32%, active trading without positive news" type: "News" locale: "en" url: "https://longbridge.com/en/news/291181479.md" description: "Jasper Therapeutics rose 12.32%; AbbVie rose 0.69%, with a transaction volume of USD 1.463 billion; Revolution Medicines rose 4.72%, with a transaction volume of USD 652 million; Fortress Biotech rose 0.91%, with a transaction volume of USD 485 million; Amgen rose 0.44%, with a market value of USD 194.3 billion" datetime: "2026-06-29T19:07:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291181479.md) - [en](https://longbridge.com/en/news/291181479.md) - [zh-HK](https://longbridge.com/zh-HK/news/291181479.md) generator: "portal-rs" --- # U.S. stock market midday update: Jasper Therapeutics up 12.32%, active trading without positive news **U.S. Stock Market Midday Update** Jasper Therapeutics, up 12.32%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie, up 0.69%. Based on recent key news: 1. On June 26, AbbVie's Skyrizi received FDA approval for pediatric psoriasis and pediatric active psoriatic arthritis, expanding the drug's pediatric label. This approval may have driven the stock price up, as the market is optimistic about its expansion in the pediatric field. 2. On June 29, AbbVie received a positive opinion from CHMP supporting the EU approval of Rinvoq for adults and adolescents with non-segmental vitiligo. This move may further enhance market confidence in AbbVie's position in the dermatology treatment field, driving the stock price up. 3. On June 29, AbbVie's partner Regenxbio administered the first dose in a late-stage study for diabetic retinopathy, receiving a $100 million milestone payment. This news may have boosted investor confidence in AbbVie's growth potential in gene therapy. Investor interest in the biopharmaceutical industry is recovering. Revolution Medicines, up 4.72%. Based on recent key news: 1. On June 29, Revolution Medicines' potential blockbuster drug completed clinical development and entered the global commercialization phase, with market expectations that it will become the next successful Biopharma company, driving the stock price up. The successful launch of this drug will provide the company with stable cash flow, reduce reliance on equity issuance, and enhance market confidence. Source: Zhitong Finance 2. On June 27, the U.S. Securities and Exchange Commission announced confirmation of Revolution Medicines' financial information, increasing investor confidence in the company's transparency, further supporting the stock price increase. Source: SEC Announcement 3. No other significant news recently. The trend of independent commercialization in the biotech industry is accelerating. Forte Biosciences, up 0.91%. Based on recent news: 1. On June 29, Vertex Pharmaceuticals has performed excellently over the past five years, with an average annual return of 19.73% and a market capitalization of $125.63 billion. This news boosted investor confidence, driving Forte Biosciences' stock price up. 2. On June 29, the IgA nephropathy market report indicated positive market trends and drivers, with significant growth expected by 2036. Forte Biosciences, as a company in the relevant field, benefited from market expectations, leading to a rise in stock price. 3. On June 29, the nephrotic syndrome market is expected to grow significantly due to treatment advancements and the introduction of innovative therapies. Vertex Pharmaceuticals' innovative therapy Inaxaplin (VX-147) further drives market expansion, benefiting Forte Biosciences' stock price The kidney disease market is expected to grow, driven by innovative therapies. **Stocks ranked among the top in industry market capitalization** Amgen rose by 0.44%. Based on recent key news: 1. On June 27, the holdings of the SCHD ETF showed that Amgen is one of its main growth drivers. As one of the top three holdings of SCHD, Amgen has performed excellently year-to-date, driving up its stock price. 2. On June 28, the FDA announced a Class II recall of the Sensipar drug. Although the recall may lead to short-term health impacts, its long-term market impact on Amgen is limited. 3. On June 29, Arrowhead Pharmaceuticals released information about new therapies that may affect market attention towards related drugs. The healthcare industry has performed strongly recently, with significant capital inflows ### Related Stocks - [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | JSPR Stock News](https://longbridge.com/en/news/295951622.md) - [Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln](https://longbridge.com/en/news/295952283.md) - [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md) - [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md) - [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**